We are pleased to invite you to a discussion entitled, “Universal access, the private sector and aid effectiveness: What can we learn from AMFm?” on November 8, 2010.
Several factors constrain access to effective treatment of malaria: development assistance has been channeled mostly through the public sector, whereas most affected individuals seek treatment in the private sector; the malaria parasite has become increasingly resistant to older and cheaper medicines; and the new antimalarial treatments (ACTs) are too expensive for many who need them. A shift in thinking and practice is underway to solve these problems through the Affordable Medicines Facility-malaria (AMFm), an innovation managed by the Global Fund.
Three elements constitute the AMFm, which works through the private, NGO and public sectors: (1) price reductions through negotiations with manufacturers, (2) a buyer subsidy in the form of a ‘co-payment’ at the top of the global supply chain and (3) interventions to support appropriate use of ACTs. Phase 1 of the AMFm, which includes 8 pilot countries, started in 2010.
Some key questions to be addressed include:
- What is the status of AMFm implementation?
- What are the early findings and challenges?
- How can traditional financing models be compared with the AMFm?
- What does it mean for our understanding of aid effectiveness and value for money?
- Date: Monday, November 8, 2010
- Time: 10:00 - 11:30 AM
- Location: Conference Room 315, 1875 Connecticut Avenue NW, Washington DC
- Guest: Dr. Olusoji Adeyi (Director, AMFm, The Global Fund to Fight AIDS, Tuberculosis and Malaria)
- Host: Robert Hecht, Managing Director, Results for Development Institute.
Please join us for the discussion and send your RSVP to gpartridge@resultsfordevelopment.org